Area of research
Infectious Diseases · Epidemiology
Research interest
Research interests include Viral gastroenteritis research and epidemiology, Respiratory viral infections research, SARS-CoV-2 and COVID-19 Research, and Animal Virus Infections Studies.
Establishment of a Neonatal Natural Transmission Model for CMV Vaccine Development.
Author Correction: BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Rational design of a highly immunogenic prefusion-stabilized F glycoprotein antigen for a respiratory syncytial virus vaccine.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age.
Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.
BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants.
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
BNT162b vaccines protect rhesus macaques from SARS-CoV-2
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
Neutralizing Activity of BNT162b2-Elicited Serum.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants.
Prefusion structure of human cytomegalovirus glycoprotein B and structural basis for membrane fusion.
Publisher Correction: COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Publisher Correction: Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
A randomized study to evaluate safety and immunogenicity of the BNT162b2 COVID-19 vaccine in healthy Japanese adults.
Novel Surrogate Neutralizing Assay Supports Parvovirus B19 Vaccine Development for Children with Sickle Cell Disease.
Neutralization of SARS-CoV-2 variants B.1.617.1 and B.1.525 by BNT162b2-elicited sera
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults